Molassiotis A, van den Akker O B, Milligan D W, Boughton B J
Department of Nursing Studies, Medical School, University of Birmingham, UK.
Bone Marrow Transplant. 1995 Aug;16(2):253-9.
Gonadal function and psychosexual adjustment were evaluated in 29 male patients after autologous and allogeneic BMT (mean post-BMT time 35.6 months). Patients were divided into groups according to their interval from transplant in order to evaluate gonadal function throughout the post-BMT years. Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were normal throughout the post-BMT years. Follicle-stimulating hormone (FSH) and luteinising hormone (LH) were increased throughout the years after BMT, suggesting moderate compensated hypogonadism. Hyperprolactinaemia was observed only in the 2nd year post-BMT and testosterone levels were normal, suggesting that Leydig cells can withstand alkylating agents or TBI. Psychosexual functioning in BMT survivors was compared with that of a group of mixed-diagnosis cancer patients (n = 30) and a group of healthy young subjects (n = 119). Long-term BMT survivors had similar psychosexual adjustment to that of other cancer patients who had received less intensive chemotherapy. Half the patients were dissatisfied with their current sex life. Major problems included impotence/erectile difficulties (37.9%), low sexual desire (37.9%) and altered body image (20.7%). However, both BMT survivors and cancer patients had significantly higher psychosexual dysfunction compared with healthy subjects. The type of chemotherapy, TBI (either single-dose or fractionated), type of transplant and post-BMT time did not correlate with either gonadal or psychosexual functioning.
对29例接受自体和异体骨髓移植的男性患者(骨髓移植后平均时间为35.6个月)的性腺功能和性心理调适进行了评估。根据移植后的时间间隔将患者分组,以便评估骨髓移植后数年的性腺功能。骨髓移植后的数年中促甲状腺激素(TSH)和游离甲状腺素(FT4)均正常。骨髓移植后的数年中促卵泡激素(FSH)和促黄体生成素(LH)均升高,提示中度代偿性腺功能减退。仅在骨髓移植后第2年观察到高泌乳素血症,睾酮水平正常,提示睾丸间质细胞可耐受烷化剂或全身照射。将骨髓移植幸存者的性心理功能与一组混合诊断癌症患者(n = 30)和一组健康年轻受试者(n = 119)进行比较。长期骨髓移植幸存者的性心理调适与接受强度较低化疗的其他癌症患者相似。一半的患者对其目前的性生活不满意。主要问题包括阳痿/勃起困难(37.9%)、性欲低下(37.9%)和身体形象改变(20.7%)。然而,与健康受试者相比,骨髓移植幸存者和癌症患者的性心理功能障碍均显著更高。化疗类型、全身照射(单剂量或分次)、移植类型和骨髓移植后时间与性腺或性心理功能均无相关性。